Loading organizations...
§ Private Profile · 2/8, Rue Gaston Rebuffat, Paris, France
Medtech company developing compact, ultra-low-field MRI scanners for healthcare providers, focused on increasing MRI accessibility.
Chipiron has raised $17.0M across 1 funding round.
Key people at Chipiron.
Chipiron has raised $17.0M in total across 1 funding round.
Founded in 2020 by Evan Kervella and Dimitri Labat, Chipiron is a medical technology company developing compact, ultra-low-field magnetic resonance imaging scanners utilizing SQUID technology to operate without shielded rooms. These portable machines function using standard electrical outlets and enable single-person operation, expanding accessibility for clinics, mobile healthcare units, and underserved patient populations. The deeptech startup closed a $17 million Series A equity financing round in March 2025 led by Blast, alongside institutional backers including the EIC Fund, Exor Ventures, and Bpifrance. This major investment builds upon previous financial backing that includes a $1,100,000 pre-seed round, a $2,700,000 seed round, and various non-dilutive grants. The enterprise will use this capital to finalize hardware prototypes and initiate clinical trials scheduled for 2026, building momentum after winning the Innovation of the Year award at VivaTech 2025.
Key people at Chipiron.
Chipiron has raised $17.0M in total across 1 funding round.
Chipiron's investors include Anthony Bourbon, Bpifrance, EIC Fund, France 2030, Herve Arditty.
Chipiron has raised $17.0M across 1 funding round. Most recently, it raised $17.0M Series A in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 30, 2025 | $17M Series A | Anthony Bourbon | Bpifrance, EIC Fund, France 2030, Herve Arditty | Announced |
Chipiron is a French deeptech startup founded in 2020 that designs and manufactures compact, ultra-low-field MRI machines to make magnetic resonance imaging accessible in standard clinics, local care centers, private practices, and mobile units.[1][2][4] The company serves the healthcare industry, primarily targeting cancer detection and other diagnostics by addressing the high cost, size, and infrastructure demands of traditional high-field MRI systems with lightweight, inexpensive, open full-body scanners.[1][2][4] Chipiron has raised $20.8M total, including a $17M Series A in 2025 led by Blast (with EIC Fund, iXcore, France2030, EIC Accelerator, and Bpifrance), following pre-seed and seed rounds, and is advancing toward prototypes and 2026 clinical trials.[1][4]
Its core product leverages patented quantum SQUID detection, AI noise cancellation, ultra-light cooling at 4K, and low-field AI reconstruction to achieve high signal-to-noise ratios (up to 10x improvement) in open environments without heavy magnets or shielding.[2]
Chipiron emerged in 2020 from the Entrepreneur First accelerator program in Paris, France, with the ambitious goal of revolutionizing MRI by creating machines with low magnetic fields.[1][3] CEO and cofounder Evan Kervella leads the team, though specific backgrounds for other founders are not detailed in available sources.[4] Early traction included $1.1M pre-seed in 2021, non-dilutive grants totaling $1.1M from 2022-2023 for R&D, and a $2.7M seed in 2023 led by Exor Ventures and Unruly Capital.[4] A pivotal moment came in May 2025 with the $17M Series A, enabling prototype finalization and hospital deployment prep.[1][4]
Headquartered at 2/8 Rue Gaston Rebuffat in Paris, the company has filed one patent (application December 2021) for a low-noise RF detection system using SQUIDs, underscoring its quantum-tech foundation.[1]
Chipiron's innovations center on overcoming traditional MRI barriers like size, cost, and site requirements:
These enable "mini-IRM" prototypes cheaper and more deployable than conventional systems.[1]
Chipiron rides the convergence of quantum sensing, AI imaging, and decentralized healthcare trends, democratizing MRI amid global shortages—exacerbated by high costs (traditional machines exceed $1M+) and installation needs.[1][2][4] Timing aligns with post-pandemic demand for point-of-care diagnostics, cancer early-detection pushes, and Europe's deeptech funding via EIC/France2030.[4] Market tailwinds include aging populations driving imaging needs and AI/quantum advances lowering barriers; Chipiron influences by pioneering clinically viable low-field MRI, potentially expanding access in underserved areas and accelerating AI-quantitative analysis for diseases like cancer.[2][4]
As an Entrepreneur First alum, it exemplifies Europe's hardware innovation ecosystem alongside peers in quantum gravimetry and lab automation.[3]
Chipiron is poised to prototype its mini-MRI in 2025 and launch clinical trials in 2026, scaling toward commercialization if trials validate performance.[1][4] Key shapers include quantum sensor maturation, AI reconstruction improvements, and regulatory nods for low-field tech; success could evolve its role from pioneer to standard-setter, transforming global MRI from centralized hospitals to ubiquitous clinics.[2][4] Risks involve trial outcomes and competition from high-field incumbents, but its $20.8M war chest and tech edge position it to fundamentally alter medical imaging accessibility—fulfilling its day-one mission to end cancer through scalable MRI.[1][2][4]
